KEYTRUDA POWDER (pembrolizumab)
MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Indication
PD-L1+, HER2-negative gastric or gastroesophageal junction adenocarcinoma
PD-L1-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of malignant epithelial tumors affecting the stomach and the junction connecting the esophagus to the stomach. Read more about PD-L1+, HER2-negative gastric or gastroesophageal junction adenocarcinoma
4 drugs 2 manufacturers
Drugs that treat it
Common PD-L1+, HER2-negative gastric or gastroesophageal junction adenocarcinoma therapies.
KEYTRUDA (pembrolizumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
TEVIMBRA (tislelizumab-jsgr)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF ESOPHAGUS·+5
BEONE MEDICINES
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+33
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with PD-L1+, HER2-negative gastric or gastroesophageal junction adenocarcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPD-L1-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of malignant epithelial tumors affecting the stomach and the junction connecting the esophagus to the stomach.
Pathophysiologically, these adenocarcinomas arise from the glandular mucosa of the upper gastrointestinal tract and lack human epidermal growth factor receptor 2 protein overexpression or gene amplification, while demonstrating cell-surface expression of programmed death-ligand 1.
Clinically identified in patients with locally advanced, unresectable, or metastatic disease, this biomarker profile delineates tumors that are unsuited for HER2-targeted therapy but possess an immune-evasive phenotype capable of dampening cytotoxic T-cell responses via the PD-1/PD-L1 signaling pathway.
- nih.gov
PD-L1-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of malignant epithelial tumors affecting the stomach and the junction connecting the esophagus to the stomach Pathophysiologically, these adenocarcinomas arise from the glandular mucosa of the upper gastrointestinal tract and lack human epidermal growth factor receptor 2 protein overexpression or gene amplification, while demonstrating cell-surface expression of programmed de...
- cancer.gov
PD-L1-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma refers to a biologically defined subset of malignant epithelial tumors affecting the stomach and the junction connecting the esophagus to the stomach Pathophysiologically, these adenocarcinomas arise from the glandular mucosa of the upper gastrointestinal tract and lack human epidermal growth factor receptor 2 protein overexpression or gene amplification, while demonstrating cell-surface expression of programmed de...
- fda.gov
Clinically identified in patients with locally advanced, unresectable, or metastatic disease, this biomarker profile delineates tumors that are unsuited for HER2-targeted therapy but possess an immune-evasive phenotype capable of dampening cytotoxic T-cell responses via the PD-1/PD-L1 signaling pathway
Personalize your experience
Follow PD-L1+, HER2-negative gastric or gastroesophageal junction adenocarcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.